title: Primary cutaneous plasmacytoma: treatment with intralesional tumour necrosis factor-alpha.
abstract: We report a case of primary multiple cutaneous plasmacytomas, without underlying multiple myeloma, treated with intralesional tumour necrosis factor-alpha (TNF-alpha). A marked reduction in tumour size, with no significant adverse effects, suggests that intralesional TNF-alpha is an effective treatment for non-solid malignant tumours. Extramedullary plasmacytoma, especially involving the skin as a primary site, has rarely been reported in the English literature. We describe the ninth reported case of multiple cutaneous plasmacytomas without underlying multiple myeloma. Intralesional tumour necrosis factor-alpha (TNF-alpha) was used to treat this disease and its anti-tumour effect quantitatively evaluated by comparing the tumour size and histological change before and after treatment.
authors.affiliation: Department of Dermatology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Tsuboi
authors.forename: R
authors.initials: R
authors.lastname: Morioka
authors.forename: H
authors.initials: H
authors.lastname: Yaguchi
authors.forename: R
authors.initials: R
authors.lastname: Shimokawa
authors.forename: M
authors.initials: M
authors.lastname: Inaba
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha